FDA Requests Teleconference to Discuss Repros Phase 2 Protocol for Proellex(R) in the Treatment of Endometriosis Last Week of August
Tickers: RPRX
FDA Requests Teleconference to Discuss Repros Phase 2 Protocol for Proellex(R) in the Treatment of Endometriosis Last Week of August
Repros Therapeutics Inc.(R) (Nasdaq: RPRX) today announced the FDA has scheduled a meeting to discuss the design of a Phase 2 endometriosis protocol for low dose oral Proellex(R) . The teleconference will be held during the last week of August 2012. The Company has submitted the Phase 2 protocol for FDA review. The Company looks forward to the Agency's advice.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.